Application of systems modelling in drug discovery; examples of impact and future direction
Neil Benson
(Pfizer UK)
Abstract:
Background: reviews of the productivity of the pharmaceutical industry have concluded that the
current business model is not optimal, or even unsustainable [2]. Various remedies for this have been
proposed, however, these do not directly address the fundamental issue; namely that it is the knowledge
required to enable good decisions in the process of delivering a drug that is largely absent; in turn,
this leads to a disconnect between our intuition of what the right drug target is and the reality of
pharmacological intervention in a system such as a human disease state. As this system is highly complex,
modelling will be required to elucidate emergent properties together with the data necessary to construct
such models. Currently, however, both the models and quality data for constructing such models are
sparse.
Ob jective: the ultimate solution to the problem of pharmaceutical productivity may be the virtual
human [1]. However, it is likely to be many years before this goal is realised in full. The current challenge
is therefore whether systems modelling can contribute to improving productivity in the pharmaceutical
industry in the interim and help to guide the optimal route to the virtual human.
Methods: the examples discussed in this presentation will use ordinary differential equation (ODE)
models to draw conclusions about optimal drug targets in given pathways, the biomarker responses that
could be used to quantify a successful outcome, the impact of pharmacology and pharmacokinetics and the
influence of access to a target. Sensitivity analysis and experiments to test model assumptions have been
used to understand and validate models. Results; models have been applied in the pain, anti-infective
and allergy disease areas, in particular relating to identifying optimal drug modalities, understanding
drug penetration to site of action in the brain and identifying novel targets in the hepatitis C virus/host
interaction.
Conclusions: systems modelling has contributed to improved decision making in projects, by identifying approaches carrying a high risk of failure, highlighting optimal biomarkers of outcome and generating
hypotheses that can be tested early in drug discovery. A key component for success was the formation
of clear questions at the outset of modelling. Future directions and the need for creating a dynamic
interaction between model building and data generation will be discussed.
[1] P. Kohl and D. Noble. Systems biology and the virtual physiological human. Molecular and Systems
Biology, 5(292), 2009.
[2] B. Munos. Lessons from 60 years of pharmaceutical innovation. Nature Reviews: Drug Discovery,
8(12):959-968, 2009.
Back
Unraveling The Spatial Regulation of Cd95-Induced Apoptosis
Roland Eils
(DKFZ Heidelberg)
Abstract:
Apoptosis occurs through a tightly regulated cascade of caspase activation. Upon induction of death
receptors, the most upstream initiator caspase-8 is activated and released into the cytosol. Different models have been proposed for the function of this release for its activity. I will present a novel approach based
on localization probes that allows to quantitatively characterize spatial-temporal activity of caspases in
living single cells. Our study reveals that while most caspase-8 substrates are cleaved with a similar
efficiency, the activity leading to caspase-8 cytosolic release is much lower. Caspase-8 is mostly active at
the plasma membrane and targeting of caspase-8 substrates to the plasma membrane can significantly
accelerate cell death. In contrast, probes that contain caspase-8 prodomain cleavage sequence targeted
to the plasma membrane are not cleaved, indicating a local reaction. Thus, compartmentalization of
enzymes and substrates is used by cells to fine tune apoptotic response and offers new possibilities to
interfere with cellular apoptotic sensitivity.
Back
Toward a molecular, cellular and systems-based theory of the adaptive immune response
Philip Hodgkin
(Walter Eliza Hall Institute)
Abstract:
When lymphocytes, the primary mediators of immunity, are stimulated they proliferate and the
receipt of soluble and cell contact mediated signals help regulate their rate of growth, survival and
differentiation. This complex system is well suited to experimental dissection, and offers a useful testing
ground for developing concepts in systems biology.
Quantitative experiments tracking individual cell fates reveal relatively simple cellular rules operating
independently within each cell. We have used time-lapse video microscopy of stimulated lymphocytes to
examine times to divide and die, and more recently times to differentiate of similar cells placed under
identical conditions [1]. These experiments reveal an extraordinary degree of variability in the behaviour
of individual cells that, irrespective, consistently leads to a high degree of predictability in the population
outcomes [2], [3]).
These and other data are consistent with a theory whereby the adaptive immune response is effectively
programmed by manipulating a small number of regulable, stochastic internal cellular mechanisms, that
when deployed in different ways are able to govern and tune the emergence of a broad range of heterogeneous cell fates. Furthermore, it seems reasonable to speculate the stochastic parameters associated
with cell fate decisions have been optimized through natural selection to best advantage the vertebrate
immune response to successfully respond to multiple different categories of pathogen.
[1] E. D. Hawkins, J. F. Markham, L. P. McGuinness, and P. D. Hodgkin. A single-cell pedigree analysis of alternative stochastic lymphocyte fates. Proceedings of the National Academy of Sciences,
106(32):13457-13462, 2009.
[2] E. D. Hawkins, M. L. Turner, M. R. Dowling, C. van Gend, and P. D. Hodgkin. A model of immune
regulation as a consequence of randomized lymphocyte division and death times. Proceedings of the
National Academy of Sciences, 104(12):5032-5037, 2007.
[3] V. G. Subramanian, K. R. Duffy, M. L. Turner, and P. D. Hodgkin. Determining the expected
variability of immune responses using the cyton model. Journal of Mathematical Biology, 56(6):861-892, 2008.
Back
Listening to the noise: stochastic fluctuations in molecular biology
Mustafa Khammash
(University of California Santa Barbara)
Abstract:
One of the challenges in the analysis and synthesis of genetic networks is that the cellular environment
in which these circuits function is abuzz with noise. Cellular noise results in random fluctuations (over
time) within individual cells and is a potential source of phenotypic variability among clonal cellular
populations. Cells appear to exploit their noisy environment in some instances and to suppress its effects
in others. Whatever the role of noise, the underlying cellular architecture cannot be fully understood
without taking stochastic noise effects into account. In this talk, we present new tools for the analysis
of noisy genetic networks and demonstrate their application for specific biological examples. We show
that noise induced fluctuations carry within them valuable information about network architecture. Far
from being a nuisance, the ever-present cellular noise acts as a rich source of excitation that propagates
through a given network and has its statistics shaped by that network's distinctive architecture. When
measured using single cell techniques, fluctuation statistics can be processed to yield information about
network connectivity and parameters that cannot be obtained using deterministic identification means.
Back
Pharmacometrics and systems biology: do they fit?
Charlotte Kloft
(Martin-Luther-University Halle-Wittenberg)
Abstract:
In drug development and therapeutic use of drugs the two aspects of increasing costs and pressure
of time are currently faced. Especially oncology presents a field with complex and individual disease
status and progression as well as with a limited number of anticancer drugs being administered in often
empirical dosing regimens and leading to highly variable success rates. Hence, understanding of the
patients' status and the disease ('system') and the development of new drugs and definition of tailored
treatment regimens seem appealing for more rationale and streamlined approaches.
Cancer is mainly caused by alterations in oncogenes and/or tumour-suppressor genes resulting in
changes in growth regulation. Technological advances especially on a molecular level in the last decade
have gained a better understanding of growth factors and the interaction with their receptors and the
down-stream signal transduction on the transformation of healthy/normal cells into maligne cells and on
regulation of cell proliferation and/or apoptosis. The knowledge in these areas has improved the abilities
to diagnose and classify cancer entities.
The fundamental challenge of anticancer drug treatment is to effectively eliminate cancer cells by a
dosing regimen that is being tolerated by the patient. Most classical cytotoxic anticancer agent do not
distinguish between healthy and cancer cells and thus inhibit essential functions in both cell populations.
A new generation of anticancer drugs has been designed to interfere with specific molecular targets that
have been identified a critical role in tumour growth or progression. In recent years, a variety of new
generation drugs has been developed targeting specific structures on the cell membranes (e.g. monoclonal antibodies) or oncogenic proteins in cancer cells (e.g. small molecule tyrosine kinase inhibitors).
Pharmacometrics aims to elucidate the relationships between dosing-drug exposure-resulting drug effects
(killing of cancer cells/toxic site effects) while incorporating knowledge of the patients and their disease.
The presentation will (i) address special features of drug cancer treatment and the current approaches
of data analysis in oncology, (ii) illustrate in case example the application of emerging tools in modelling
and simulation, (iii) highlight the improvements of cross-disciplinary interaction and (iv) finally indicate
future challenges to be met.
In future, effective integration of knowledge in biomarkers for disease, pharmacokinetics and pharmacodynamics, as well as combining approaches in systems biology and modelling/simulation might
streamline drug development and increase the risk/benefit ratio of therapeutic use in the individual
patient.
[1] C. Kloft, J. Wallin, A. Henningsson, E. Chatelut, and M. O. Karlsson. Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across
Anticancer Drugs . Clinical Cancer Research, 12(18):5481-5490, 2006.
[2] B.-F. Krippendorff, K. Kuester, C. Kloft, and W. Huisinga. Nonlinear Pharmacokinetics of Therapeutic Proteins Resulting From Receptor Mediated Endocytosis. Journal of Pharmacokinetics and
Pharmacodynamics, 36(3):239-260, 2009.
Back
Function by design: how emergent design properties shape
the biological function of the RAS-RAF-MEK-ERK/MAPK
Walter Kolch
(Systems Biology Ireland)
Abstract:
The RAS-RAF-MEK-ERK pathway controls a variety of fundamental cellular processes including cell
proliferation, transformation, differentiation, motility and apoptosis. While individual biochemical steps
are vey well studied, it still remains enigmatic how this pathway can mediate so many diverse biological
functions with high specificity and fidelity. Here, we will discuss how design properties of the ERK
pathway determine its regulation and biological function analysing the following three aspects:
1) Analysing pathway topology by Bayesian inference. Topology can have a decisive influence on the
activation kinetics and biological function of a pathway. Although we can describe complex networks in
terms of components, we cannot easily determine which topology the cell actually uses to transduce a
specific signal. Using Bayesian inference-based modelling we can use measurements of a limited number
of biochemical species combined with multiple perturbations to reliably distinguish between different
plausible pathway topologies.
2) The role of feedback loops in shaping ERK response kinetics. The three-tiered RAF-MEK-ERK
kinase cascade functions as an amplifier. However, this pathway also contains a number of negative
feedback loops that in combination with the amplifier module produce interesting effects, for instance
increasing drug resistance, constraining responses within a cell population, and conveying robustness
against perturbations in the amplifier.
3) The role of noise. The ERK pathway converts receptor signals that can be of variable and fluctuating strengths into robust biological responses. Thus, there must be mechanisms to filter true signals from
noise. We have analysed such mechanisms by a combination of biochemical measurements and mathematical (deterministic and probabilistic) modelling. We find that the activation of ERK is different
between individual cells and cell populations depending on dose and duration of the input. Explicitly
incorporating protein expression variability in kinetic models, we demonstrate that analogue behaviour
on the single cell levels can generate digital output on the population level. This conversion relies on
stochastic noise in protein expression between individual cells and the existence of a negative feedback
loop from ERK to Ras/Raf-1 that makes responses of individual cells more graded. Thus, systems responses, which depend on a complex interplay between pathway topologies, the interaction kinetics, and
activation dosage are dramatically shaped by noise in protein expression.
Back
Assessing key players in disease relevant pathways
Ursula Kummer
(University of Heidelberg)
Abstract:
Modeling the dynamics of biochemical systems has become as essential and integral part of systems
biology. The rational behind this fact is that a true understanding of biochemical networks must eventually result in valid predictions about the behaviour of these network in the living cell. In most cases,
such predictions will only be possible in the context of concise descriptions of the networks which allow
a thorough analysis. Mathematical descriptions are doubtless concise and allow for a multitude of ways
to analyse their behaviour. Thus, the identification of key players by conducting sensitivity analyses has
been suggested and used for drug target identifications in the past.
However, in general, a lot of precise experimental data is needed to build a quantitative, computational
models with predictive power. Still, sensitivity analyses are often conducted locally, for one specific set
of parameters. This poses a problem for the application in drug target identification. Thus, not knowing
many of the parameters asks for more global approaches.
In this presentation, I will introduce different strategies for a global assessment of key players in
biochemical pathways. As an example a systems biology investigation of interferon signalling is presented.
This study identified IRF-9 as a key player in the signalling pathway which is crucial in anti-viral defense.
Back
Multi-Pathway Network Analysis of Epithelial Cell Responses in Inflammatory Environments
Douglas Lauffenburger
(Massachusetts Institute of Technology)
Abstract:
Cellular responses to external stimuli depend upon dynamic features of multi-pathway network signaling, and thus ultimate phenotypic behavior is influenced in a complex manner by both cellular environment and intrinsic cellular properties. We have established across the past half-decade that multi-variate
systems analysis employing 'data-driven' computational modeling methods aimed at quantitative experimental data within a 'cue-signal-response' paradigm are capable of comprehending these convoluted
effects for relatively simplified in vitro cell culture examples. In this Workshop contribution, I will present
recent extensions of this foundational work along avenues including emphasis on application to in vivo
contexts and on connection to interactome databases, focused on epithelial cell responses in inflammatory
environments.
Back
Regulatory T cell control of pathogenic and effector T cells
- implications for the development of new therapeutics for
cancer and autoimmunity
Kingston Mills
(Trinity College Dublin)
Abstract:
Immune homeostasis is dependent on a balance between regulatory and effector/pathogenic T cells and
manipulating this balance may be a promising approach for the treatment of cancer and autoimmunity.
It is now well established that IL-17-producing CD4+ T cells (Th17 cells) play a pathogenic role in
many autoimmune diseases, a function previously attributed exclusively to IFN-γ -secreting Th1 cells.
Furthermore, Th17 cells can function with Th1 cells to mediate protective immunity to infection and
may also be important in immunity to tumors. Regulatory T (Treg) cells can suppress pathogenic
T cells directed against self-antigens and thereby prevent autoimmunity, and limit immunopathology
during infection, but can also suppress protective immunity to pathogens and to tumors. Stimulation of
innate immune cells, especially dendritic cells (DC), by pathogen-associated molecular patterns (PAMPs)
through TLRs, NLRs, RLRs and CLRs, provide the signals for maturation and cytokine production
(signals 2 and 3) for T cell activation. However other innate cells, including NK cells and γδ T cells,
also play a role in induction of Th1 and Th17 cells respectively. We have shown that TLR and NLR
agonists induce IL-1 α and IL-1 β as well as IL-23, which synergize to promote activation of memory
Th17 cells. IL-1 and IL-23 also stimulate IL-17 production by γ δ T cell, which act in an autocrine manner
to stimulate activation of Th17 cells. The induction of function of Th17 cells is regulated by cytokines
secreted by the other ma jor subtypes of T cells, especially IL-10 and TGF-β production by Treg cells.
The induction of natural and adaptive Treg cells is stimulated by TGF-β , IL-10 and IL-27 in response
to certain virulence factors from pathogens that have evolved to subvert protective immunity, but also
in response to TLR and NLR agonists and this constrains their potential as adjuvants and therapeutics
against infection and cancers. We have examined the signalling pathways in PAMP-activated DC that
promote the innate cytokines that drive T cell responses. We have shown that inhibitors of MAP kinase
and PI3K signalling pathways can block IL-10 and TGF-β , while sparing or enhancing IL-12 production,
thereby promote Th1, but not Treg cells. This has been successfully applied to a therapeutic intervention
against tumors in pre-clinical models. finally, we have identified approaches for activation of regulatory
cytokine production by innate immune cells for selective induction of Treg cells, without Th1 or Th17
cells. These approaches been effective in pre-clinical models of autoimmunity and cancer and are also
being translated to clinical studies in humans.
Back
Multiscale Modeling of Hepatitis C Virus Infection
Alan Perelson
(Los Alamos National Laboratory)
Abstract:
Mathematical models of viral infection and treatment for illnesses caused by agents such as HIV,
hepatitis C virus (HCV) and hepatitis B virus, have been successful in uncovering basic features underlying
the pathogenesis of these diseases, such the rate of viral production in infected individuals and the lifespan
of infected cells. In the case of HCV infection, new direct acting antiviral agents that interfere with
various intracellular molecular processes are in clinical trials. In order to model the action of these
agents, new multiscale models that simultaneously consider intracellular events as well events at the
cellular and extracellular level are needed. I will discuss our recent progress in this area and show that
certain features of HCV infection that we had previously deduced based on analyzing patient responses
to interferon and ribavirin therapy may have to be revised based on new data and these new multiscale
models. Further, drug resistance to HCV protease inhibitors when used as monotherapy has appeared in
clinical trials more rapidly than ever seen before in the treatment of any infectious disease - as early as
the second day of therapy 5-20% of viral isolates have been shown to be resistant. Models have revealed
how this is possible but have also raised some unanswered questions about the rapid in vivo growth of
drug resistant virus.
Back
Long-Lasting Therapeutic Effects of Desynchronizing Brain
Stimulation
Peter Tass
(Institute of Neuroscience and Medicine, Jülich)
Abstract:
A number of brain diseases, e.g. movement disorders such as Parkinson's disease, are characterized
by abnormal neuronal synchronization. Within the last years permanent high-frequency (HF) deep brain
stimulation became the standard therapy for medically refractory movement disorders. To overcome
limitations of standard HF deep brain stimulation, we use a model based approach. To this end, we
make mathematical models of affected neuronal target populations and use methods from statistical
physics and nonlinear dynamics to develop mild and efficient control techniques. Along the lines of a
top-down approach we test our control techniques in oscillator networks as well as neural networks. In
particular, we specifically utilize dynamical self-organization principles and plasticity rules. In this way,
coordinated reset (CR) stimulation [1], an effectively desynchronizing brain stimulation technique, has
been developed. The goal is not only to counteract pathological synchronization on a fast time scale,
but also to unlearn pathological synchrony by therapeutically reshaping neural networks [2]. I shall
present the theory, results from both experiments in MPTP monkeys and a first clinical application.
CR stimulation can also be applied non-invasively, e.g. as acoustic CR stimulation for the treatment of
tinnitus. The latter is characterized by abnormal delta band synchronization e.g. in the auditory cortex.
I shall present results from a single-blinded multicenter clinical trial in 63 patients.
[1] P. Tass. A model of desynchronization deep brain stimulation with a demand-controlled coordinated reset of neural subpopulations. Biological Cybernetics, 89:81-88, 2003.
[2] P. Tass and M. Majtanik. Long-term anti-kindling effects of desynchronizing brain stimulation: a
theoretical study. Biological Cybernetics, 94:58-66, 2006.
Back
|
|